

Virulence Genes Detection and Antimicrobial Susceptibility of *Staphylococcus pseudintermedius* Isolates from Canine Skin Infection in Chennai, India

M. AnandaChitra¹  · C. Jayanthi² · B. Nagarajan²

Received: 26 December 2015 / Revised: 1 June 2016 / Accepted: 21 June 2016 / Published online: 14 July 2016
© The National Academy of Sciences, India 2016

Abstract *Staphylococcus pseudintermedius* (SP) is the major pathogen incriminated in the skin infections of dog. Identification of SP requires molecular methods. The incidence of methicillin resistant SP (MRSP) is increasing worldwide and it is a growing concern in treating pet animals. The prevalence of SP and MRSP from skin infections of dog in India has not been studied previously. Hence, the present study was aimed to isolate SP from common skin infections of dog in Chennai, India and to characterize these isolates. A total of 53 SP organisms were isolated from 91 samples of skin infection accounting for 59 % of isolation rate. Labrador was a major breed from which isolation was made. Pantone–Valentine leucotoxin (*Luk-I*) and *S. intermedius* exfoliative toxin (*siet*) genes were detected in all SP isolates but staphylococcal protein A homologue (*spsQ*) gene was detected only in 36 % of the SP isolates. Out of 53 isolates, 17 % were found to be strong and 19 % to be moderate producers of biofilm and 28 % were classified as MRSP due to possession of the *mecA* gene. Most isolates were sensitive to tetracycline and ciprofloxacin and least sensitive to erythromycin and trimethoprim/sulphamethaxazole. The authors first time reported the isolation of MRSP, characterization of SP isolates by detecting virulence genes, biofilm forming

ability and susceptibility to antimicrobials in Chennai, India.

Keywords *Staphylococcus pseudintermedius* · Virulence genes · Antimicrobial susceptibility · Biofilm formation

Introduction

Bacterial pyoderma and otitis are the most common dermatological problems encountered in small animal clinical practice. *Staphylococcus* sp. is predominantly incriminated in canine skin disease. Among them, coagulase positive *Staphylococcus pseudintermedius* (SP) is the most important opportunistic commensal pathogen in dogs. SP is a normal inhabitant of skin and mucosal surface of dogs and is commonly obtained from the nares, mouth, groin, axilla and perianal areas [1]. SP is a leading cause of skin and ear infections and it also causes infections of other body tissues and cavities, post-operative wound infections, urinary tract infections and necrotizing fasciitis in dogs and cats [2]. SP was first described in 2005 by Devriese [3]. It has been categorized under *Staphylococcus intermedius* group (SIG) which includes *S.intermedius*, *S.pseudintermedius* and *S.delphini* as they could not be differentiated phenotypically. SP can be differentiated from other members biochemically [4] but there is no phenotypic marker. Hence, molecular methods such as PCR–RFLP [5, 6], MALDI-TOF MS [7] and multiplex PCR [8] are required for species differentiation. PFGE [9], MLST [9], Spa typing [10] and *SCCmec* [11] are used for strain typing. Incidence of methicillin resistant SP (MRSP) is increasing worldwide but prevalence differs in various geographical locations. Colonization by SP isolates on the skin of dog owners,

✉ M. AnandaChitra
anandachitra.m@tanuvas.ac.in

¹ Department of Veterinary Microbiology, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu 600 007, India

² Department of Veterinary Clinical Medicine, Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu 600 007, India

veterinarians and attending staff has been reported [12]. Moreover, cases of human infections caused by SP have been increasing due to the available molecular methods to identify SP in diagnostic/academic laboratories [13]. As there is no previous study on the isolation and characterization of SP isolates from India, the present study was attempted to determine the prevalence of SP from skin infections of dogs in Chennai, India, to identify MRSP and to detect their virulence genes and antimicrobial susceptibility.

Material and Methods

Bacteria Isolation and Identification

Samples were collected between February 2013 and February 2014 from dogs with skin infections, brought to the Dermatology Unit of Teaching Veterinary Clinical Complex, Madras Veterinary College, Chennai. Isolation and identification of *S. pseudintermedius* isolates was done as described previously [14].

Detection of Virulence Genes

Virulence factor genes such as *S. intermedius* exfoliative toxin (*siet*), Panton Valentine-like toxins (*LukS-I* and *LukF-I*) and staphylococcal protein A homologue (*SpsQ*) were detected by PCR using primers and conditions as given in the Table 1. PCR was performed in a reaction volume of 10 μ l containing approximately 100–150 ng of genomic DNA, 5 pmol of each primer and 2 \times master mix (Ampliqon, Denmark). Cycling conditions were 94 $^{\circ}$ C for 3 min, followed by 30 cycles of denaturation at 94 $^{\circ}$ C for 30 s, annealing at 55/60 $^{\circ}$ C for 30 s, extension at 72 $^{\circ}$ C for 30 s and a final extension cycle of 5 min at 72 $^{\circ}$ C. PCR products were loaded on a 2 % agarose gel for electrophoresis, visualized with ethidium bromide and documented.

Antimicrobial Susceptibility Test

Antimicrobial susceptibility testing was performed by disk diffusion method on Mueller–Hinton agar and isolates were classified as sensitive, intermediate and resistant based on recommendations of CLSI document M100-S21 (M2) [15]. Ampicillin (10 μ g), cephotoxime (30 μ g), ciprofloxacin (5 μ g), erythromycin (15 μ g), oxacillin (1 μ g), tetracycline (30 μ g), trimethoprim (1.25 μ g)/sulphamethaxazole (23.75 μ g) antimicrobial discs used in the present study were procured from HiMedia Pvt Ltd, India.

Biofilm Formation

Biofilm formation was carried out as per the method described by Hassan et al. [16] using a quantitative spectrophotometric microliter plate assay. The interpretation of biofilm production was done based on the OD value as given below:

OD of isolate \leq OD of control (ODc) = No biofilm formation; ODc < OD of isolate = Weak biofilm formation; 2 \times ODc \leq OD of isolate = Moderate biofilm formation; 4 \times ODc \leq OD of isolate = High biofilm formation.

Results and Discussion

Prevalence of *S. pseudintermedius* Isolates

A total of 91 samples were collected between February 2013 and February 2014 from various skin infections of dogs of different breeds, age and sex. SP was isolated from 53 (59 %) animals. The major breed from which SP was isolated was Labrador (30 %) followed by mixed breed dogs (21 %), Pug (11 %), Spitz (11 %), German Shepherd (9 %) and 17 % of other breeds. A higher rate of isolation of SP have been reported in pyoderma cases from Japan (76 % in 2009) [17], Germany (76 %) [18] and south Korea (61 %) [19]. An almost similar rate of isolation of 52 % from both diseased and healthy dogs was noticed in

Table 1 Primers used in this study along with amplicon size, annealing temperature and references

S. no.	Primer name	Sequences (5'–3')	Amplicon size (bp)	Annealing temperature ($^{\circ}$ C)	References
1	<i>SIspsa</i>	F-AACCTGCGCCAAGTTTCGATGAAG R-CGTGGTTTGCTTTAGCTTCTTGGC	820	55	[10]
2	<i>Luk S</i>	F-CCTGTCTATGCCGCTAATCAA R- AGGTCATGGAAGCTATCTCGA	572	55	[20]
3	<i>Luk F</i>	F-TTGGAAGTTACCGCCAACA R-AGCAGAAAATGGGGCGTT	300	55	This study
4	<i>siet</i>	F-TGCGGGTCTCAATCTTTAAC R-CTTTCAACTCTGCACGCAATC	465	60	This study

Poland [21] and 55 % from healthy dogs in Tunisia [22]. However, a lower isolation rate was observed with 40 % in Guide dog school in Finland [23], 16 % from healthy and diseased dogs in south China [24] and 26.5 % from pyoderma cases in north China [25].

Generally, pyoderma caused by SP is either simple infection or complex infection that is associated with underlying disease such as allergies (flea allergy, atopic dermatitis, food allergy), internal disease (hypothyroidism or hyperadrenocortism), seborrhoeic conditions (folliculitis) or parasitic disease (demodicosis). In the present study, 25 isolates were from dogs with simple pyoderma and others with complex pyoderma. Ten dogs were infected with demodicosis, 5 dogs each with otitis and allergy and 4 dogs each with other parasitic infection and other causes.

Age did not significantly influence skin infection caused by SP. Prevalence of SP infection was 40 % in dogs less than 1 year old, 32 % in dogs 2–4 years old and 28 % in dogs more than 4 years old. SP isolates obtained from females (66 %) were twice than that of males (34 %). A similar higher incidence of nasal colonization of *S. aureus* in females than male dogs was observed in Hong Kong [26]. In another study in USA, no difference in the susceptibility to infection caused by SP among male and female dogs was noticed [27]. The rate of colonization of *S. aureus* in humans was reported more in males than females in Bangalore city [28] and Andhra Pradesh [29] in India; whereas, the prevalence of MRSA was found to be higher in females than that of males in Agra [30] and Himachal Pradesh [31] in India. Hence, these results of the previous studies on SP or *S. aureus* colonization/infection in humans and dogs have been variable in regards to age or sex predilection and there is no conclusive evidence.

***S. intermedius* Exfoliative Toxin (SIET)**

All the *S. pseudintermedius* isolates possessed the *S. intermedius* exfoliative toxin (*siet*) gene and this result corroborates with the studies of canine SP isolates of Korea [32], Poland [21] and Tunisia [22]. Dogs injected with purified SIET develop clinical signs such as erythema, exfoliation and crusting, which are signs of canine pyoderma [33]. *S. aureus* exfoliative toxins are extremely specific serine proteases and function as ‘molecular scissors’ during skin infection and cleave desmosomal cadherins only in the superficial layers of the skin, which is directly responsible for the clinical manifestation of staphylococcal scalded skin syndrome in human. Recent reports demonstrated that 3–4 % of methicillin sensitive *S. aureus* (MSSA) strains carry the *eta* or *etb* gene [34, 35], whereas around 10 % of methicillin resistant *S. aureus* (MRSA) are *eta* positive [35]. However, the significance of

all SP strains isolated from both healthy and diseased cases possessing *siet* gene is not known.

Panton and Valentine Leucocidin (PVL) Like Toxin (*Luk-I*)

Panton and valentine leucocidin (PVL) found in certain strains of *S. aureus* is a bicomponent—LukS-PV and LukF-PV, pore forming leukotoxin that causes leukocyte destruction and tissue necrosis. A similar bicomponent leukotoxin Luk-I, encoded by two genes, *lukS/F*, was also detected in SP and toxins were found to be cytotoxic to various polymorphonuclear cells, monocytes and macrophages [20]. All the SP isolates characterized in the present study possessed *Luk-I* genes. Other studies involving SP isolates from both healthy and diseased dogs were also positive for *Luk S/F* genes [21, 22, 36, 37]. The clinical sequelae of PVL-positive *S. aureus* infections tend to be more severe than PVL-negative *S. aureus* [38]. However, such clarity could not be established in SP isolates as it is present in both healthy and diseased dogs. Studies to detect *S. aureus* PVL gene in SP isolates from diseased dogs in Switzerland [39] and in Belgium [40] revealed that none of the SP isolates were PVL- positive.

Staphylococcal Protein A Homologue (*spsQ*)

Staphylococcal protein A homologue gene (*spsQ*) was detected in 19 (36 %) of the isolates and among them, 8 isolates were MRSP. A higher prevalence of protein A homologue and Clumping Factor of 54.5 % canine *S. intermedius* strains was observed on latex agglutination test in Japan [41]. However, a lower prevalence of 14.2 % SP isolates from infected dogs and 1.4 % from healthy dogs of Poland was reported for protein A by dot blot assay [21]. These SP isolates from dogs of Poland were also characterized for *siet*, *Luk-I*, *thermonuclease* and *agr* virulence genes by PCR. Protein A was the only phenotypic pathogenicity factor that distinguished infected and non-infected dogs in their study and it has unambiguously been confirmed that the strains from infected dogs synthesize protein A markedly and more frequently than those from healthy dogs. In the present study, SP from healthy dogs was not studied. Staphylococcal protein A is a cell wall anchored surface protein with four or five domains that each can bind to the Fc region of IgG. The interaction between protein A and IgG coats the surface of the cell with IgG molecules that cannot be recognized by the neutrophil Fc receptor and activates the complement by the classical pathway as a result of incorrect orientation. The study explains the anti-phagocytic effect of protein A in vitro and for that reason it is considered a virulence factor in several models of animal infection.

In *S. aureus*, staphylococcal protein A is encoded by *spa* gene where as in SP, two orthologues of *spsA–spsP* and *spsQ* were detected [42]. In that study, the prevalence of *spsP* and *spsQ* were tested in 20 SP isolates and it was found that *spsQ* was present in 12/20 strains whereas *spsP* was present only in 8/20 isolates which also possessed *spsQ* orthologues. In the present study, primers originally designed to target *spsQ* were used and further studies are required to understand the prevalence of *spsP* orthologue and typing of SP isolates of Indian origin. The significance of possessing two orthologues of protein A in SP and its relevance in pathophysiology of SP colonization and infection in dogs need to be investigated. The Xr repeat region *spa* is widely used to type *S.aureus* strains for epidemiological analysis and the same technique was adapted to type SP isolates by targeting the Xr repeat region of *spsQ* [10].

Biofilm Formation

The majority of *S. pseudintermedius* isolates evaluated in the present study were either weak (30 %, 16/53) or had no ability (34 %, 18/53) to produce biofilm, with only 17 % (9/53) being classified as strong and 19 % (10/53) as moderate biofilm producers. There was no difference between MRSP and MSSP isolates in biofilm formation. However, the number of MRSP isolates evaluated in the study was relatively less. In a Norwegian study [43], all 23 MRSP isolates analyzed produced biofilm and belonged to sequence type (ST) 71, producing significantly more biofilm as compared to other STs. Similarly, all 20 MRSP isolates evaluated by Diccio et al. [44] formed biofilm and also reported that clarithromycin was ineffective in eradicating MRSP biofilm at therapeutic doses. Out of 140 SP isolates from dogs in Canada and United States, 96 % were able to produce biofilm and the biofilm production was not significantly different amongst isolates from clinical infections as compared to isolates obtained from colonized dogs [45]. Biofilm production by *S. pseudintermedius* plays an important role in the pathophysiology of disease and in

potential colonization. It could be a contributing factor in the rapid and worldwide emergence of MRSP [11].

Antimicrobial Susceptibility

Among the 53 SP isolates, 15 isolates (28 %) were confirmed to be methicillin resistant *S. pseudintermedius* (MRSP) with the detection of *mecA* gene. MRSP was first reported in 2005 and since then more isolates of MRSP have been isolated from various countries with differing prevalence rate. The prevalence of MRSP identified in the present study is comparatively lesser than those reported from south China (48 %) [24], north China (44 %) [25] and USA (63.3 %) [46]. However, the prevalence of MRSP varies significantly between regions, as it was observed to be 21 % in Italy [47], 18 % in Korea [19], 11.4 % in Japan [17], 4.6 and 20 % in dogs with various clinical conditions and bitches with different reproductive disorders in Lithuania [48], 7.5 % in Croatia [36], 7.4 % in Germany [18], and no methicillin resistance was detected in SP isolates from canine pyoderma cases in West Indies [49].

In the present study, one *mecA* negative SP isolate was found to be resistant to oxacillin (Table 2). A similar observation of *mecA* negative oxacillin resistant SP isolates was reported by Feng et al. [24] and Kang et al. [50]. Hawraa et al. [51] and Elhassan et al. [52] also reported *mecA*-negative oxacillin resistant staphylococci. The first MRSA strain encoding a divergent *mecA* gene (now designated as *mecC*) was discovered from bovine mastitis milk sample and it has also been found in animal and human isolates [53]. The presence of *mecC* gene was not evaluated in the isolated SP organisms used in the present study. However, these findings provided clear evidence that there are mechanisms other than the presence of *mecA* gene responsible for methicillin resistance. Hence, it is highly recommended to use both phenotypical traditional Kirby-Bauer method and genotypic *mecA* and *mecC* detection by PCR to identify methicillin resistant staphylococci.

Among other tested antimicrobials, SP isolates were most susceptible to tetracycline (60 %), ciprofloxacin

Table 2 Susceptibility pattern of *S.pseudintermedius* isolates against various antimicrobial agents

S. no.	Antimicrobial agents	No. of isolates (N = 53)		
		Sensitive (%)	Intermediate (%)	Resistant (%)
1.	Oxacillin	30 (56.58)	7 (13.20)	16 (30.18)
2.	Ciprofloxacin	27 (50.94)	12 (22.64)	14 (26.42)
3.	Tetracycline	32 (60.35)	10 (18.86)	11 (20.75)
4.	Cefotaxime	21 (39.61)	18 (33.95)	14 (26.40)
5.	Ampicillin	18 (33.95)	11 (20.75)	24 (45.26)
6.	Erythromycin	11 (20.75)	26 (49.04)	16 (30.18)
7.	Trimethoprim/sulphamethaxazole	14 (26.40)	23 (43.39)	16 (30.18)

(51 %) and cefotaxime (39 %) and least sensitive to erythromycin (21 %) and trimethoprim/sulphamethoxazole (26 %). Feng et al. [24] reported that more than 70 % of the SP isolates from south China were resistant to erythromycin, trimethoprim and penicillin and >50 % isolates were resistant to ciprofloxacin and enrofloxacin. Out of 74 SP isolates from Korea, the highest antibiotic resistance was observed towards penicillin, tetracycline, trimethoprim and erythromycin [18]. More than 60 % of the SP isolates from Japan in 2009 were found to be resistant to ampicillin and >40 % of the isolates were resistant to kanamycin, tetracycline, enrofloxacin and ofloxacin and only 27 % of the isolates were resistant to erythromycin [16]. Antimicrobial susceptibility study of 106 SP isolates from Croatia revealed that the resistance was more to ampicillin (78 %) followed by kanamycin (42 %), tetracycline (37.7 %), erythromycin (37.7 %), clindamycin (32 %) and chloramphenicol (26.4 %) [20]. Differences in geographical locality, investigation period, method of antimicrobial susceptibility test carried out, variation in the treatment of choice with available antimicrobial drugs in the pertinent country might be the possible reasons for the variations in the reported resistance rate to different antimicrobials.

The present study is the first comprehensive investigation on the isolation of SP and detection of various virulence genes, biofilm forming ability and antimicrobial susceptibility in Indian SP isolates. Further research is required to understand the prevalent type of SP in this geographical region and genetic background of resistance profile for antimicrobials.

Conclusion

The present study revealed the moderate prevalence of MRSP in dogs in India. Among the virulence factors evaluated, SP isolates differed in the presence of staphylococcal protein A homologue gene and biofilm forming ability. But, there was no difference in these factors between SP and MRSP isolates of India. Characterization of other potential virulence factors and the zoonotic capability of this organism to the populations should be ascertained and the public should be educated in how to handle pet dogs and cats that may have staphylococcal infections.

Acknowledgments The authors thankfully acknowledge the Vice-Chancellor, TANUVAS for providing the infrastructure and facilities to carry out this research.

Compliance with Ethical Standards

Conflict of interest The author declares that there is no conflict of interest.

References

- Rubin JE, Chirino-Trejo M (2011) Prevalence, sites of colonization, and antimicrobial resistance among *Staphylococcus pseudintermedius* isolated from healthy dogs in Saskatoon, Canada. *J Vet Diagn Investig* 23:351–354
- Weese JS, van Duijkeren E (2010) Methicillin-resistant *Staphylococcus aureus* and *Staphylococcus pseudintermedius* in veterinary medicine. *Vet Microbiol* 140:418–429
- Devriese LA, Vancanneyt M, Baele M, Vanechoutte M, De Graef E, Snauwaert C, Cleenwerck I, Dawyndt P, Swings J, Decostere A, Haesebrouck F (2005) *Staphylococcus pseudintermedius* sp. nov., a coagulase-positive species from animals. *Int J Syst Evol Microbiol* 55(Pt 4):1569–1573
- Sasaki T, Kikuchi K, Tanaka Y, Takahashi N, Kamata S, Hiramatsu K (2007) Reclassification of phenotypically identified *Staphylococcus intermedius* strains. *J Clin Microbiol* 45:2770–2778
- Bannoehr J, Franco A, Iurescia M, Battisti A, Fitzgerald JR (2009) Molecular diagnostic identification of *Staphylococcus pseudintermedius*. *J Clin Microbiol* 47:469–471
- Blaiotta G, Fusco V, Ercolini D et al (2010) Diversity of *Staphylococcus* species strains based on partial kat (catalase) gene sequences and design of a PCR-restriction fragment length polymorphism assay for identification and differentiation of coagulase-positive species (*S. aureus*, *S. delphini*, *S. hyicus*, *S. intermedius*, *S. pseudintermedius*, and *S. schleiferi* subsp. *coagulans*). *J Clin Microbiol* 48:192–201
- Decristophoris P, Fasola A, Benagli C et al (2011) Identification of *Staphylococcus intermedius* group by MALDI-TOF MS. *Syst Appl Microbiol* 34:45–51
- Sasaki T, Tsubakishita S, Tanaka Y et al (2010) Multiplex-PCR method for species identification of coagulase-positive staphylococci. *J Clin Microbiol* 48:765–769
- Black CC, Solyman SM, Eberlein LC et al (2009) Identification of a predominant multilocus sequence type, pulsed-field gel electrophoresis cluster, and novel staphylococcal chromosomal cassette in clinical isolates of *mecA*-containing, methicillin-resistant *Staphylococcus pseudintermedius*. *Vet Microbiol* 139:333–338
- Moodley A, Stegger M, Ben Zakour NL, Fitzgerald JR, Guardabassi L (2009) Tandem repeat sequence analysis of staphylococcal protein A (*spa*) gene in methicillin-resistant *Staphylococcus pseudintermedius*. *Vet Microbiol* 135:320–326
- Perreten V, Kadlec K, Schwarz S, Andersson UG, Finn M, Greko C et al (2010) Clonal spread of methicillin-resistant *Staphylococcus pseudintermedius* in Europe and North America: an international multicentre study. *J Antimicrob Chemother* 65:1145–1154
- vanDuijkeren E, Kamphuis M, van der Mije IC et al (2011) Transmission of methicillin-resistant *Staphylococcus pseudintermedius* between infected dogs and cats and contact pets, humans and the environment in households and veterinary clinics. *Vet Microbiol* 150:338–343
- Stegmann R, Burnens A, Maranta CA, Perreten V (2010) Human infection associated with methicillin-resistant *Staphylococcus pseudintermedius* ST71. *J Antimicrob Chemother* 65:2047–2048
- AnandaChitra M, Jayanthi C, Nagarajan B (2015) Detection and sequence analysis of accessory gene regulator genes of *Staphylococcus pseudintermedius* isolates. *Veterinary World* 8(7):902–907
- Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement. In: CLSI document M100-S21 (M2), vol 30, nos 1, 15. Wayne, Pennsylvania

16. Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M (2011) Evaluation of different detection methods of biofilm formation in the clinical isolates. *Braz J Infect Dis*. doi: [10.1590/S1413-86702011000400002](https://doi.org/10.1590/S1413-86702011000400002)
17. Onuma K, Tanabe T, Sato H (2011) Antimicrobial resistance of *Staphylococcus pseudintermedius* isolates from healthy dogs and dogs affected with pyoderma in Japan. *Vet Dermatol* 23:17–e5
18. Ruscher C, Lübke-Becker A, Wleklinski CG, Soba A, Wieler LH, Walther B (2009) Prevalence of methicillin-resistant *Staphylococcus pseudintermedius* isolated from clinical samples of companion animals and equidae. *Vet Microbiol* 136:197–201
19. Yoon JW, Lee KJ, Lee SY, Chae MJ, Park JK, Yoo JH et al (2010) Antibiotic resistance profiles of *Staphylococcus pseudintermedius* isolates from canine patients in Korea. *J Microbiol Biotechnol* 20:1764–1768
20. Futagawa-Saito K, Sugiyama T, Karube S, Sakurai N, Ba-Thein W, Fukuyasu T (2004) Prevalence and characterization of leukotoxin-producing *Staphylococcus intermedius* in isolates from dogs and pigeons. *J Clin Microbiol* 42:5324–5326
21. Garbacz K, Zarnowska S, Piechowicz L, Haras K (2013) Pathogenicity potential of *Staphylococcus pseudintermedius* strains isolated from canine carriers and from dogs with infection signs. *Virulence* 4(3):255–259
22. Gharsa H, Ben Slama K, Lozano C, Gómez-Sanz E, Klibi N, Ben Sallem R, Gómez P, Zarazaga M, Boudabous A, Torres C (2013) Antimicrobial resistance, virulence genes, and genetic lineages of *Staphylococcus pseudintermedius* in healthy dogs in Tunisia. *Microb Ecol* 66:363–368
23. Grönthal T, Ollilainen M, Eklund M, Piiparinen H, Gindonis V, Junnila J, Koulumies LS, Liimatainen R, Rantala M (2015) Epidemiology of methicillin resistant *Staphylococcus pseudintermedius* in guide dogs in Finland. *Acta Vet Scand* 57:37. doi: [10.1186/s13028-015-0129-8](https://doi.org/10.1186/s13028-015-0129-8)
24. Feng Y, Tian W, Lin D, Luo Q, Zhou Y, Yang T, Deng Y, Liu YH, Liu JH (2012) Prevalence and characterization of methicillin-resistant *Staphylococcus pseudintermedius* in pets from South China. *Vet Microbiol* 160:517–524
25. Wang Y, Yang J, Logue CM, Liu K, Cao X, Zhang W, Shen J, Wu C (2012) Methicillin-resistant *Staphylococcus pseudintermedius* isolated from canine pyoderma in North China. *J Appl Microbiol* 112:623–630
26. Boost MV, O'Donoghue MM, James A (2008) Prevalence of *Staphylococcus aureus* carriage among dogs and their owners. *Epidemiol Infect* 136:953–964
27. Bryan J, Frank LA, Rohrbach BW, Burgette LJ, Cain CL, Bemis DA (2012) Treatment outcome of dogs with methicillin-resistant and methicillin-susceptible *Staphylococcus pseudintermedius* pyoderma. *Vet Dermatol* 23:361–e65
28. Bouchiat C, El-Zeenni N, Chakrakodi B, Nagaraj S, Arakere G, Etienne J (2015) Epidemiology of *Staphylococcus aureus* in Bangalore, India: emergence of the ST217 clone and high rate of resistance to erythromycin and ciprofloxacin in the community. *New Microbe New Infect* 7:15–20
29. Rao BN, Srinivas B (2012) A prospective study of methicillin resistant *Staphylococcus aureus* (MRSA) in a teaching hospital of rural setup. *J Pharm Sci Innov* 1(2):37–40
30. Goyal A, Diwakar MK, Bhooshan S, Goyal S, Agrawal A (2013) Prevalence and antimicrobial susceptibility pattern of methicillin-resistant *Staphylococcus aureus* [MRSA] isolates at a Tertiary Care Hospital in Agra, North India—a systemic annual review. *IOSR J Dent Med Sci* 11(6):80–84
31. Sharma S, Mall A (2011) The prevalence, antibiogram and characterization methicillin resistant *Staphylococcus aureus* among the patients from the Doon Valley hospitals. *Afr J Microbiol Res* 5(21):3446–3451
32. Yoon JW, Lee GJ, Lee SY, Park C, Yoo JH, Park HM (2010) Prevalence of genes for enterotoxins, toxic shock syndrome toxin 1 and exfoliative toxin among clinical isolates of *Staphylococcus pseudintermedius* from canine origin. *Vet Dermatol* 5:484–489
33. Terauchi R, Sato H, Hasegawa T, Yamaguchi T, Aizawa C, Maehara N (2003) Isolation of exfoliative toxin from *Staphylococcus intermedius* and its local toxicity in dogs. *Vet Microbiol* 94:19–29. doi: [10.1016/S0378-1135\(03\)00048-8](https://doi.org/10.1016/S0378-1135(03)00048-8)
34. Megevand C, Gervaix A, Heininger U, Berger C, Aebi C et al (2010) Molecular epidemiology of the nasal colonization by methicillin-susceptible *Staphylococcus aureus* in Swiss children. *Clin Microbiol Infect* 16:1414–1420
35. Sila J, Sauer P, Kolar M (2009) Comparison of the prevalence of genes coding for enterotoxins, exfoliatins, panton–valentine leukocidin and tsst-1 between methicillin-resistant and methicillin susceptible isolates of *Staphylococcus aureus* at the university hospital in Olomouc. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 153:215–218
36. Matanović K, eMekić S, Šeol B (2012) Antimicrobial susceptibility of *Staphylococcus pseudintermedius* isolated from dogs. *Veterinarski Arhiv* 82(5):505–517
37. Ruscher C, Lübke-Becker A, Semmler T, Wleklinski CG, Paasch A, Soba A, Stamm I, Kopp P, Wieler LH, Walther B (2010) Widespread rapid emergence of a distinct methicillin- and multidrug-resistant *Staphylococcus pseudintermedius* (MRSP) genetic lineage in Europe. *Vet Microbiol* 26:340–346
38. Gillet Y, Issartel B, Vanhems P, Godail-Gamot et al (2002) Association between *Staphylococcus aureus* strains carrying gene for panton–valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. *Lancet* 359:753–759
39. Descloux S, Rossano A, Perreten V (2008) Characterization of new staphylococcal cassette chromosome mec (SCCmec) and topoisomerase genes in fluoroquinolone- and methicillin-resistant *Staphylococcus pseudintermedius*. *J Clin Microbiol* 46(5):1818–1823
40. Bardiau M, Yamazaki K, Ote I, Misawa N, Mainil JG (2013) Characterization of methicillin-resistant *Staphylococcus pseudintermedius* isolated from dogs and cats. *Microbiol Immuno* 57(7):496–501. doi: [10.1111/1348-0421.12059](https://doi.org/10.1111/1348-0421.12059)
41. Futagawa-Saito K, Ba-Thein W, Sakurai N, Fukuyasu T (2006) Prevalence of virulence factors in *Staphylococcus intermedius* isolates from dogs and pigeons. *BMC Vet Res* 2:4. doi: [10.1186/1746-6148-2-4](https://doi.org/10.1186/1746-6148-2-4)
42. Bannoehr J, Ben Zakour NL, Reglinski M, Inglis NF, Prabhakaran S, Fossum E et al (2011) Genomic and surface proteomic analysis of the canine pathogen *Staphylococcus pseudintermedius* reveals proteins that mediate adherence to the extracellular matrix. *Infect Immun* 79(8):3074–3086
43. Osland AM, Vestby LK, Fanuelson H et al (2012) Clonal diversity and biofilm forming ability of methicillin-resistant *Staphylococcus pseudintermedius*. *J Antimicrob Chemother* 67:841–848
44. Diccio M, Neethirajan S, Singh A, Weese JS (2012) Efficacy of clarithromycin on biofilm formation of methicillin-resistant *Staphylococcus pseudintermedius*. *BMC Vet Res* 8:225
45. Singh A, Walker M, Rousaaeau J, Weese JS (2013) Characterization of the biofilm forming ability of *Staphylococcus pseudintermedius* from dogs. *BMC Vet Res* 9:93
46. Black CC (2010) Methicillin resistance in *Staphylococcus pseudintermedius*. Ph D Dissertation, University of Tennessee. http://trace.tennessee.edu/utk_graddiss/775
47. De Lucia M, Moodley A, Latronico F, Giordano A, Caldin M, Fondati A, Guardabassi L (2011) Prevalence of canine methicillin resistant *Staphylococcus pseudintermedius* in a veterinary diagnostic laboratory in Italy. *Res Vet Sci* 91:346–348

48. Ruzauskas M, Couto N, Kerziene S, Siugzdiniene R, Klimiene I, Virgailis M, Pomba C (2015) Prevalence, species distribution and antimicrobial resistance patterns of methicillin-resistant staphylococci in Lithuanian pet animals. *Acta Vet Scand* 57:27. doi:[10.1186/s13028-015-0117-z](https://doi.org/10.1186/s13028-015-0117-z)
49. Hariharan H, Gibson K, Peterson R, Frankie M, Matthew V, Daniels J, Martin NA, Andrews L, Paterson T, Sharma RN (2014) *Staphylococcus pseudintermedius* and *Staphylococcus schleiferi* subspecies *coagulans* from canine pyoderma cases in Grenada, West Indies, and their susceptibility to beta-lactam drugs. *Vet Med Int*. doi:[10.1155/2014/850126](https://doi.org/10.1155/2014/850126)
50. Kang MH, Chae MJ, Yoon JW, Kim SG, Lee SY, Yoo JH, Park HM (2014) Antibiotic resistance and molecular characterization of ophthalmic *Staphylococcus pseudintermedius* isolates from dogs. *J Vet Sci* 15(3):409–415. doi:[10.4142/jvs.2014.15.3.409](https://doi.org/10.4142/jvs.2014.15.3.409)
51. Hawraa WA, Al-Dulaimi T, Al-Marzoqi AH (2014) Phenotypic detection of resistance in *Staphylococcus aureus* isolates: detection of (*mec A* and *fem A*) gene in methicillin resistant *Staphylococcus aureus* (MRSA) by polymerase chain reaction. *J Nat Sci Res* 4:112–118
52. Elhassan MM, Ozbak HA, Hemeg HA, Elmek MA, Ahmed LM (2015) Absence of the *mecA* Gene in methicillin resistant *Staphylococcus aureus* isolated from different clinical specimens in Shendi City. *Bio Med Res Int, Sudan*. doi:[10.1155/2015/895860](https://doi.org/10.1155/2015/895860)
53. García ÁL, Holden MTM, Lindsay H, Webb CR, Brown DFJ et al (2011) Methicillin resistant *Staphylococcus aureus* with a novel *mecA* homologue in human and bovine populations in the UK and Denmark: a descriptive study. *Lancet Infect Dis* 11:595–603